

Institut de
recherche



Research
Institute

McGill University
Health Centre

Infectious Diseases and Immunity in Global Health Program
Programme en maladies infectieuses et immunité en santé mondiale

*Improving Global Health through Research
La recherche pour le bénéfice de la santé mondiale*

Centre universitaire
de santé McGill



<http://idigh.ca>

IDIGH Program Symposium 2016

Friday September 23, 2016

Atrium and Amphitheater of the RI-MUHC, 1001 Boul Decarie




Table of Contents

Welcome from the Symposium Organizers – P3

Symposium Program – P4

Thank You to Our Sponsors/Partners – P5

Bio-sketches of the Symposium Speakers – P6 & P7

Bio-sketches of the Workshop Speakers – P8 & P9

IDIGH Program Overview – P10

Abstracts/Profiles of Technology Workshop – P11 to P14

VWR Profile – P15

Booth and Registration Layout – P16

How to Get Here – P17

List of Attendees – P18 to P22

Welcome From The Symposium Organizers

Dear Symposium Attendees,

On behalf of the [IDIGH Program](#), it is with great pleasure that we welcome you to join our [Annual Symposium](#) at the RI-MUHC on Friday September 23, 2016.

As in the previous year, the objective of our upcoming IDIGH Program Symposium is to provide a platform for all participants to interact and exchange research ideas in the area of infectious diseases, immunity and global health. This year's symposium will bring together 298 attendees from more than 50 different academic research centres, biotech and pharmaceutical companies as well as vendors and service providers. Hopefully, the synergies emerging from our symposium will lead to innovative new collaborations not only among the RI- MUHC/McGill groups but the larger Canadian and international Global Health communities.

We are grateful for the participation of our guest speakers (Drs. Eric Cohen, Brian Ward, Charles Wells and Michel G. Bergeron). They will not only present their latest discoveries and new trends in infectious diseases and immunity research in global health but also share their experiences and lessons in the importance of private-academic partnerships, the potential for academic spin-offs and how to translate research findings into improved health for all.

We have invited vendors to showcase their innovative products and services. Furthermore, four companies will present their cutting edge technologies in fundamental and translational research in broader fields including infectious diseases, immunity, respiratory diseases and cancer. We thankfully acknowledge the contributions of our sponsors/partners. Without their generous support it would not be possible to hold this symposium free of charge for the participants.

We thank our volunteers Shane Baistrocchi, Sabrina Bartolucci, Anastasia Cheng, Alexia De Simone, Lynn Dery Capes, Genelle Harrison, Hilary Hendin, Breanna Hodgins, Roman Istomine, Cynthia Kanagaratham, Maxime Lemieux, Wilian Macedo, Marcia McKenzie, Hanna Ostapska, Kai Sheng, James Stewart, Kaitlin Winter, Harry Yang and Mina Youssef for their help and assistance, ensuring the success of our symposium.

We are confident that the symposium will provide a good opportunity for all participants to learn and to mingle with like-minded researchers, trainees, clinician scientists, service providers and to develop new collaborations and partnerships.

Enjoy the symposium!

Jing Liu, Joanne Krief, Madhu Pai, Marcel Behr and Erwin Schurr

IDIGH Program Symposium 2016

Time	Speaker	Affiliation	Presentation or Activity
11:00 am	Sponsor Product Show Begins at the Atrium		
12:00 pm	Lunch for Registrants by the Amphitheatre		
Technology Workshop & Door Prizes at the Amphitheatre			
1:00 pm	Mathieu Larivière	ThermoFisher Scientific	Ion Torrent AmpliSeq: Custom Design with Simplicity for Next Generation Sequencing
1:20 pm	John Lesnick	LABCYTE	Moving Liquids with Sound: Transforming Life Science with the Echo Series of Acoustic Liquid Handlers
1:40 pm	Brigitte Simons	SCIEX	Turn-Key LC-MS with New Keys: An Up-To-Date Review of SCIEX's iMETHODs for Pre-Configured and Kit-Based LC-MS Applications in Biomarker Validation
2:00 pm	Michael Smith	Illumina	Blood and Guts: The Convergence of Cancer and Microbial Applications of NGS
2:30 pm	Coffee Break, Door Prizes and 1 st iPad 4 64 GB Draw Courtesy of PharmaMedSci at the Atrium		
Symposium & iPad 4 Draw Courtesy of Novoprotein at the Amphitheatre, Wine & Cheese at the Atrium			
3:00 pm	Erwin Schurr	Leader, IDIGH Program RI-MUHC Professor, McGill University	Welcome and Introductory Remarks
3:05 pm	Eric Cohen	Professor, IRCM - UdeM Director, Laboratory of Human Retrovirology Leader, Canadian HIV Cure Enterprise (CanCURE)	HIV Accessory Proteins and HIV Persistence
3:40 pm	Brian Ward	Professor of Medicine & Microbiology, Division of Infectious Diseases, JD MacLean Centre for Tropical Diseases McGill University	Dancing with Elephants: The Art of Surviving Academic-Industry Collaborations
4:15 pm	Charles Wells	Associate VP / Head of Development Infectious Diseases, Sanofi	Developing Infectious Disease Therapeutic Strategies and the Critical Role of Partnerships
4:50 pm	Michel G. Bergeron	Professor, Founder, Centre de recherche en infectiologie de l'Université Laval	From Bedside Needs to Innovation in Rapid Molecular Diagnostics
5:25 pm	Vassili Papadopoulos	CEO, RI-MUHC Professor, McGill University	Closing Remarks
5:30 pm	All	All	Wine & Cheese, 2 nd iPad Draw

IDIGH Program Symposium 2016

MAJOR SPONSORS



illumina®

AB SCIEX

ViiV
Healthcare

gsk

PharmaMedSci
Quality Equipment Solutions

ThermoFisher
SCIENTIFIC

novoprotein
The ultimate protein choice

GENERAL SPONSORS

BioLegend®
Enabling Legendary Discovery™

PEPROTECH.
Manufacturer of Quality Cytokine Products

SARSTEDT

affymetrix
eBioscience

GenomeQuébec

MILLIPORE
SIGMA

FLUIDIGM®

WISENT
BIOCENTER

MACS
Miltenyi Biotec

Promega

SONY
New technology in Flow Cytometry

MJS
BioLynx
INC.

NEW ENGLAND
BioLabs
making technologies in life sci. a success

Cell Signaling
TECHNOLOGIES™
The England Britain Ltd is the exclusive
Canadian distributor for Cell Signaling Technology, Inc.

Mandel

STEMCELL
TECHNOLOGIES

BD

CANADIAN
LIFE SCIENCE

ESSEN
BIO SCIENCE

biotechne®

Think Possible
BioTek

CEDARLANE®

Diamedica

BIO-RAD

PALL

Corning

Fisher Scientific

FroggysBio

PerkinElmer
For the Better

Institut de
recherche
Centre universitaire
de santé McGill



Research
Institute
McGill University
Health Centre

McGill



GLOBAL
HEALTH
PROGRAMS
PROGRAMMES DE
SANTÉ
MONDIALE

McGill

Faculty of
Medicine


Centre
international
de TB McGill



McGill
International
TB Centre

Bio-sketches of the Symposium Speakers


Dr. Michel G. Bergeron



Professor of microbiology and infectious diseases (ID), clinician, scientist, researcher and entrepreneur, Dr. Michel G. Bergeron is the founder of the Centre de recherche en infectiologie of Université Laval in Québec City. A world renowned researcher, he is the author of more than 400 publications. Dr. Bergeron and his team were the first to develop innovative rapid real-time DNA-based tests which allow the specific identification, directly from a clinical sample, of microbes and their antibiotic resistance genes in less than one hour instead of 2 to 3 days using standard “Pasteur” microbiology (Bergeron *et al.*, NEJM 343:175-9, 2000). Several FDA approved real-time PCR tests to diagnose and better control healthcare-associated infections are derived from his research laboratory. These tests, insuring real-time diagnostics and treatment, are saving many lives and preventing the spread of nosocomial infections and antimicrobial resistance while reducing

healthcare costs. In 1995, to transform discoveries into products, he created Infectio Diagnostic (IDI) Inc. which was acquired by Becton Dickinson (BD) in 2006. These high clinical value tests are fabricated in Québec City (350 employees) and commercialized in 50 countries by BD. Dr. Bergeron has recently developed, with his transdisciplinary research team, a simple point-of-care (POC) microfluidic real-time PCR device that is easy for almost everyone to operate whether at bedside, in the emergency room, in physician offices, in pharmacies, or even in dispensaries in the developing world. This platform allows near patient <1h diagnostic results which guide appropriate management of infections on the spot. This technology now manufactured by GenePOC, a company he founded, will revolutionize medical practice

Dr. Éric A. Cohen



Doctor Éric A. Cohen is Director of the Laboratory of Human Retrovirology at the Institut de recherches cliniques de Montréal (IRCM). He is also Professor of Virology at the Department of Microbiology, Infectiology and Immunology at the Université de Montréal and recipient of the IRCM-Université de Montréal Chair of Excellence in HIV Research. Dr. Cohen holds a B.Sc. in Biochemistry from McGill University and a Ph.D. in Molecular Biology from l' Université de Montréal. During his postdoctoral training at the Dana Farber Cancer Institute at Harvard University, he contributed significantly to the global efforts to characterize the

genetic organization and structure of the Human Immunodeficiency Virus (HIV). His initial work led to the co-discovery of two virulence factors, Vpr and Vpu, which belong to a class of HIV proteins, named accessory proteins, whose role is to promote viral persistence in spite of the host adaptive and innate/intrinsic immune responses. Dr. Cohen's current research directions aim to better understand HIV-host interactions regulating viral replication, transmission, and persistence. His studies on the interactions between HIV and antiviral effectors of the host innate immune response have fostered a transforming understanding of HIV persistence and opened new avenues for the development of HIV curative strategies. Dr. Cohen is a member of the editorial board of *Retrovirology* and a fellow of the Royal Society of Canada and the Canadian Academy of Health Sciences. Since 2014, Dr Cohen leads the Canadian HIV Cure Enterprise (CanCURE: www.cancurehiv.org), a pan-Canadian multidisciplinary research consortium dedicated to the study of long-lived HIV reservoirs and the development of effective therapeutic strategies towards an HIV Cure.



Dr. Brian James Ward

Dr Ward received medical training at McGill, University of London and Johns Hopkins (Internal Medicine, Tropical Medicine, Infectious Diseases & Microbiology). His research training began as a Rhodes scholar (1977-1980) and continued at Johns Hopkins (1986-1990). He joined the McGill Medical faculty in 1991 where he is currently full professor. He is chair of CAIRE (Canadian Association for Immunization Research and Evaluation) and represents Canada/CIHR on the GloPID-R Scientific Advisory Board (Global Infectious Diseases Preparedness Research). He also sits on the Institutional Advisory Board of the CIHR Institute for Health Promotion & Prevention. Since 2010 and 2015 respectively, he has served as Medical Officer for Medicago, a rapidly growing company using plants to make vaccines and Avixx, a smaller US company using attenuated Salmonella strains as vaccine vectors. His research

interests include nanoparticle vaccines, adjuvants & immunomodulators, micronutrient-virus interactions, and parasite diagnostics. He has published >225 peer-reviewed manuscripts/chapters and is a fellow of the Canadian Academy of Health Sciences. His international work has been carried out with colleagues in Peru, Zimbabwe, Sudan, Haiti and Venezuela among other countries.



Dr. Charles Wells

Charles Wells currently serves as Associate Vice President and Head of Development for the Infectious Diseases Therapeutic Area at Sanofi-U.S. based in Bridgewater, NJ, having joined the organization in September 2015. Prior to joining Sanofi he served as the Senior Medical Director for the development and registration of delamanid for treatment of multidrug resistant-tuberculosis at Otsuka Pharmaceuticals in Rockville, Maryland, from 2007-2015, and previously, he served as Chief of the International Research and Programs Branch of the Division of Tuberculosis Elimination at the U.S. Centers for Disease Control

and Prevention (CDC) during 2000-2007. He is a native of North Carolina where he completed his medical studies at the University of North Carolina at Chapel Hill in 1992 and then completed his post-graduate medical training in internal medicine and infectious diseases at Emory University and the CDC in Atlanta, Georgia, during 1992-1998.

Bio-sketches of the Technology Workshop Speakers



Mathieu Lariviere

Field Application Scientist for Thermo Fisher Scientific
Mathieu has a diploma in Biochemistry from University Laval as well as his Masters. He worked for 9 years at Ste-Justine Hospital on promoter regions of genes involved in ALL (Acute Lymphoblastic Leukemia) and pharmacogenomics response to ALL treatment. Managed the NGS platform at Ste-Justine for 2 years and for the past 4.5 years has been a NGS Field Application Scientist for Thermo Fisher Scientific.



John Lesnick,

Senior Scientist, Applications, Labcyte Inc, Sunnyvale, California. John Lesnick has worked in the Drug Discovery and Development field for over 20 years. He has contributed assay development expertise for many therapeutic areas from target validation to preclinical toxicology. His expertise with cell biology and biochemical molecular pharmacology has been applied to applications in genomics and drug discovery. John has extensive knowledge in automation and instrumentation.



Dr. Brigitte Simons

Is a market development manager at SCIEX, representing the academic and government research market segments for SCIEX's LC-MS and CE-MS business. Her primary scientific specialization focuses on the applications of accurate mass spectrometry based solutions for lipidomics and metabolomics, as well as biotherapeutic protein characterization and it's forecasting to drug development in the pharmaceutical industry. To effectively achieve the very best in scientific consultation regarding LC-MS assays and modern approaches to data analysis, Brigitte manages key accounts across Canada and the biopharma hub of Massachusetts (New England) where strong partnerships between academia and industry continue to spearhead the industrialization of analytical technologies that are highly regarded by federal funding initiatives in Canada. Prior to working at SCIEX, Brigitte received her Ph.D. in Chemistry at the University of Ottawa. She then completed two research post-doctoral

fellowships at the Centre for Biologics Research at Health Canada (Ottawa, CAN) and the National Institute of Heart Lung and Blood (Bethesda, MD, USA).



Michael Smith



Earned his PhD in Anatomy and Cell Biology from Columbia University in 2000 while studying mitochondrial inheritance and actin dynamics in the budding yeast, *Saccharomyces cerevisiae*. He did his postdoctoral work with Mike Snyder at Yale University where he studied yeast-bacterial interactions. During this time, he was first introduced to high throughput methods and next generation sequencing technologies. In 2009, after working as an R&D Scientist at Invitrogen, he joined Illumina as a Field Application Scientist covering Upstate NY and CT. Since 2010, he has worked in the Northeast of the US and Eastern Canada as a technical expert in sequencing methodologies.


IDIGH Program Overview

Le programme en maladies infectieuses et immunité en santé mondiale (MIISM) réunit l'expertise, les ressources et les points forts de la recherche en maladies infectieuses, en immunologie et en santé mondiale dans trois domaines. Il comprend 18 groupes de recherche en laboratoire au Centre de biologie translationnelle (CBT), 16 groupes ciblant les recherches évaluatives en santé et en épidémiologie au Centre de recherche évaluative en santé (CRES) et 25 groupes menant des recherches cliniques en association avec le Centre de médecine innovatrice (CMI). Le programme est conçu pour agir comme catalyseur de la recherche innovatrice et pour établir des pipelines de découvertes sur des maladies choisies. Il vise aussi à former la prochaine génération de scientifiques en recherches biomédicales, cliniques et évaluatives, et à contribuer au renforcement des capacités des pays pauvres qui sont affectés de façon disproportionnée par les maladies liées à la pauvreté (p. ex., la tuberculose, la lèpre, le virus de l'immunodéficience humaine (VIH) et les maladies tropicales négligées). L'interaction synergétique des approches méthodologiques assure que les recherches et la formation réalisées au sein du programme sont interdisciplinaires et multidisciplinaires, et ont une forte composante translationnelle.

The Infectious Diseases and Immunity in Global Health Program (IDIGH) unites expertise, resources and research strengths in infectious diseases, immunology and global health across three domains. It comprises 18 laboratory-based research groups at the Centre for Translational Biology (CTB), 16 groups with a focus on epidemiology and health outcomes research from the Centre for Outcomes Research and Evaluation (CORE), and 25 groups conducting clinical research associated with the Centre for Innovative Medicine (CIM). The program is designed to act as a catalyst for innovative research and establish discovery pipelines in select diseases. It also aims to train the next generation of scientists in biomedical, clinical, and health outcomes research, and to facilitate capacity-building in resource-poor countries that are disproportionately affected by diseases of poverty (for example, tuberculosis, leprosy, human immunodeficiency virus (HIV), and neglected tropical diseases). The synergistic interaction of methodological approaches ensures that research and training conducted within the program is interdisciplinary and multidisciplinary, with a strong translational focus.

For more details of our IDIGH Program, please visit our [website](http://idigh.ca) (<http://idigh.ca>).





TITLE

MOVING LIQUIDS *with* SOUND

Transforming Life Science with the Echo Series of Acoustic Liquid Handlers

@ 1:20 PM

SPEAKER

JOHN LESNICK

Sr. Scientist, Applications, Labcyte Inc., Sunnyvale, CA

ABSTRACT

Labcyte's award-winning products use acoustic energy to precisely and accurately transfer liquids across a wide range of fluid types and volumes with no user calibration required. This capability significantly improves data quality and reliability, while eliminating or substantially reducing costs associated with pipette tips, reagents and waste disposal. Equally important, it conserves precious samples and enables highly accurate assay miniaturization, dramatically improving productivity.

The Echo system is a flexible liquid handling platform allowing assay set up at volumes from nanoliter to microliters at speeds that can keep pace with the demands of a variety of applications. The Echo system is seamlessly integrated into Labcyte's Access™ workstations with Tempo™ automation software and Echo applications software.

We will discuss the latest advancements with the Echo liquid handler and Labcyte automation systems to address an expanding range of work flows. Drug Discovery, Cancer Research, Infectious Disease and Genomics using the Echo 500 series liquid handlers are less expensive, more versatile and have improved data quality.



Echo® 525 LIQUID HANDLER

LABCYTE 
The Future of Science is Sound

 @LabcyteInc
info-us@labcyte.com

© 2016 LABCYTE INC. All rights reserved. Labcyte®, Echo®, and the Labcyte logo are registered trademarks or trademarks of Labcyte Inc., in the U.S. and/or other countries.

The image features the Illumina logo in the top left, with the 'i' in orange and 'llumina' in grey. To the right, there are blue, textured, branching structures resembling DNA or microbial growth. At the bottom, a wavy ribbon of DNA sequence letters (A, T, C, G) flows from left to right, transitioning through colors from orange to green to purple.

illumina®

“Blood and Guts: The Convergence of Cancer and Microbial Applications of NGS”

Illumina has an extensive portfolio of next generation sequencing systems, from the powerful, high-throughput HiSeq systems to the ultra fast and low cost MiniSeq system. Powered by TruSeq and Nextera library preparation methodologies, each sequencer features the industry’s simplest, most streamlined workflow and delivers unparalleled data quality for a wide range of research projects. Well-suited for microbial applications, the MiSeq was tabbed as the US FDA’s choice for food safety surveillance. The ability to identify clinically relevant bacteria and viruses quickly and accurately has made NGS the top choice for pathogen surveillance by government agencies and hospitals worldwide. Cancer, as a disease of the genome, is best studied by sequencing. Identifying SNPs, structural variants and copy number variations reveals types and subtypes of neoplasia. Recently, the intersection of host variations leading to cancer and the constituents of the microbiota has been revealed. Here, we will profile how sequencing technologies are revolutionizing the fields of oncology and microbiology. From clinical applications to environmental profiling, Illumina’s sequencing technology has transformed the field and changed the way we see the world.



“Turn-key LC-MS with New Keys; An up-to-date review of SCIEX’s iMETHODs for pre-configured and kit-based LC-MS applications in biomarker validation”

Mass spectrometers are unique in that they can directly analyze any biological molecule susceptible to ionization. The biological studies of human metabolites and proteins using contemporary mass spectrometry technology (metabolomics and proteomics, respectively) have been ongoing for over a decade. Relatively few biomarkers have been translated into clinical tests however some significant advances have been made for deploying multi-lab validated LC-MS methods for clinical research programs. This review will discuss some key technological developments that have occurred to offer complete iMETHODs; LC methods, internal standards, validated SOPs and kit-based methods towards improving the quantitation of peptides, metabolites and lipids. These kit-based methods will be explained and their results in biological milieus.

iontorrent

Ion AmpliSeq technology

Sequence with simple, rapid NGS workflows

ThermoFisher
SCIENTIFIC

“Ion Torrent AmpliSeq: Custom Design with Simplicity for Next Generation Sequencing”

Ion Torrent AmpliSeq™ technology is a capture method using ultra high multiplexing amplification. This technology is a very robust method using limited amount as input (10ng or lower) and is compatible with challenging degraded samples. Ion Torrent AmpliSeq™ technology is highly customizable (any genome) can be used for targeting resequencing (DNA), detection of RNA fusions, RNA gene expression, and many more applications. In this presentation, we will present results of 2 custom Ion Torrent AmpliSeq™ design (DNA & RNA design) to expose the simplicity of the technology.



Distributor of the following companies



Authorized Distributor
GE Healthcare




VWR Sales Representative: Christine_Nguyen@vwr.com

Booth Assignments

1. Essen
2. BD
3. Biotek
4. Fisher/Corning
5. Stemcell
6. ThermoFisher (Manon Rousseau)
7. Canadian Life Science
8. Sony
9. Peprotech
10. BioLegend
11. Novoprotein
12. Fluidigm
13. Genome Quebec
14. Pall/VWR
15. LABCYTE
16. Miltenyi Biotec
17. Starstedt
18. Promega
19. Affymetrix
20. Bio-techne
21. Wisent
22. Milipore Sigma
23. Biolynx
24. PharmaMedSci
25. Mandel
26. NEB/Cell Signaling
27. Froggabio/Perkin Elmer
28. Bio-Rad
29. Diamed
30. Cedarlane
31. ThermoFisher (Isabelle & Fred)
32. Merck (Pharma in Amphitheater)

Front Entrance



Vendor Booths

Security Desk

Hallway Entrance

Amphitheater

Coffee Break

Hallway

Lunch

Kitchen

Merck

Climbing

Coffee shop

Registration desks & door prize tables

Venue of the Event:

E-S1 of block E (seen below in red), 1001 Boul Decarie, Glen Site, Montreal, Quebec H4A 3J1

How to get here:



Metro: Vendôme station on the Orange Line is a few minutes walking distance

Bus: 17, 37, 90, 102, 104, 105 and 124 stop at Vendôme station, and 78, 24 and 63 stop near the MUHC Glen site and 77 stops at the MUHC Glen site private road

Commuter trains: Vendôme metro station connects to: Saint-Jérôme, Candiac and Vaudreuil/Hudson

Car: easily accessible from highways 15, 20 and 720. The public Glen parking lot entrance is on Décarie Blvd- Parking: Entrance (seen below light blue arrow) cost: \$25 per day

Elevator: press **S1**, and follow the signs to E block (seen below in red)



List of Attendees

Abouchacra Sammy

FroggaBio

Abouelazm Nihad

Experimental Medicine
MUHC

Adhikari Anupam

Microbiology and Immunology
RI-MUHC

Alenezi Wejdan

RI-MUHC

Alexandres Nicoletta

Sales
Mandel Scientific Company Inc

Allard Benoit

Medicine
McGill

Alriyami Maha

Experimental Medicine
McGill

Alvarez Fernando

Microbiology and Immunology
McGill University

Amorim Raquel

Department of Medicine
McGill University

Angers Isabelle

Medicine
RI-MUHC

Asin Milan Odalis

Medical Affairs
Merck Canada

Atehortua Veronica

RI-MUHC

Baistrocchi Shane

Microbiology and Immunology
McGill

Balassy Zsombor

Biomedical
McGill University

Baranci Mirela

Vaccines, Hospital & Acute Care
Merck Canada Inc.

Baron Christian

ViiV Healthcare

Bartolucci Sabrina

Experimental Medicine
McGill

Beaulieu Edith

PerkinElmer, Inc.

Belanger Edith

MilliporeSigma

Bergeron Michel G.

Professor , Founder
Centre de recherche en infectiologie
de l'Université Laval

Beriau Patrick

Corning

Bernard Nicole

Medicine
RI-MUHC McGill

Besso Dominique

Experimental Medicine
McGill University

Bidulka Patrick

McGill Global Health Programs
McGill

Bin Dhuban Khalid

Immunology
McGill University

Blanchard Luc

Thermo Fisher Scientific

Bouchard Julien

FroggaBio

Boudjemai Yacine

Merck

Bourbonniere Martin

Affymetrix

Brewer Angela

RI-MUHC

Brunet Daniel

Promega Corporation

Budry Lionel

GSK

Burelle Chantal

Chronic Viral Illness Service
RI-MUHC

Butiaeva Liliia

Endocrinology and Metabolism
McGill University

Cartman Annie

MilliporeSigma

Casgrain Pierre-André

Medicine
RI-MUHC

Caya Chelsea

RI-MUHC

Chagnon Pierre

Thermo Fisher Scientific

Charland Jean-Francois

Sales
Mandel Scientific Company Inc

Cheng Anastasia

Experimental Medicine
McGill University

Chouiali Fazila

Histopathology Platform
RI-MUHC

Cinti Alessandro

Medicine
McGill University

Coblentz Jacqueline

Pathology
RI-MUHC

Cohen Eric

Institut de Recherches Cliniques de
Montréal

Côté Catherine

Chromatographic Specialties Inc.

Coyne Erin

Biochemistry
RI-MUHC

Cui Wei

Human Genetics
MUHC-RI

Cyr Louis

RI-MUHC

Daftary Amrita

Epidemiology
McGill

Daher Aïcha

Lady Davis Institute for Medical
Research

Dai Meiou

Medicine
McGill University

Dang Thao

VWR

De Simone Alexia

Microbiology and immunology
McGill university

Dejgaard Kurt

Biochemistry
McGill

Dembele Marieme

Experimental Medicine
McGill University

Denechaud Gaetane

MJSBioLynx Inc.

Derderian Seta

Experimental Medicine
McGill University

Dery Capes Lynn

RI-MUHC

Descoteaux Albert

INRS- Institut Armand-Frappier

Di Battista Giovanni (John)

Medicine
McGill University and MUHC-RI

Diniz Atayde Vanessa

MUHC

Domenech Pilar

Infectious Diseases

RI-MUHC

Dominguez Kenneth

Department of Urology

McGill University

Downey Jeff

Pathology

McGill University

Du Xiaoyu

Experimental Medicine

RI-MUHC

Dunn Jonathan Luke

Microbiology and Immunology

McGill University

Dupuy Franck

Experimental Medicine

RI-MUHC

Duquette Philippe

Atomy and Cell Biology

McGill - MUHC

Ebrahimizadeh Walead

Experimental Surgery

McGill University

Ede Mauricio

Merck Canada Inc.

Elhousseini Hassan Muhamad

Experimental surgery

McGill, MUHC

Elzein Samar

Endocrinology

RI-MUHC

Essagian Charles

Medicine

RI-MUHC

Farooq Zeeshan

Fluidigm Corporation

Fava Vinicius

Human Genetics

McGill University

Favreau Dominique

Cardiology, Interl Medecine

RI-MUHC

Fay Nikta

STEMCELL Technologies

Feng Shi Bo

RI-MUHC

Flarakos Themis

Canadian Life Science

Fu Min

RI-MUHC

Garibay Maria

Interfax Systems Inc

Garic Dusan

Human Genetics

McGill University

Gasbarrino Karina

Experimental Medicine

McGill University

Gatignol Anne

Medicine

LDI-McGill University

Gavino Christina

RI-MUHC

Ghozlan Mostafa

Experimental Medicine

McGill- RI-MUHC

Giordano Christian

Medecine

McGill university

Golabi Nahid

Experimental Medicine

McGill

Goldberg Sam

McGill Alumnus

Gómez Palou Monica

Experimental Medicine

McGill University

Graf Peter

Affymetrix - ThermoFisher

Grenier Jean-Christophe

Pediatrics

CHU Sainte-Justine

Gros Philippe

Biochemistry

McGill University

Guarneri Frank

Fisher Scientific

Guerrero Kether

Human genetics

RI-MUHC

Gyorkos Theresa

Epidemiology, Biostatistics and

Occupatiol Health

McGill University

Hachim Ibrahim

Experimental Medicine

McGill University

Hafiane Anouar

Biochemistry

McGill

Haider Nida

Experimental Medicine

McGill University

Hamel Lucie

Urology-Oncology

RI-MUHC

Hamel Nancy

Research Institute McGill University

Health Center

Harrison Genelle

Human Genetics

McGill University

He Qing Wen

Biochemistry

MUHC

Hendin Hilary

Microbiology and immunology

McGill university

Hendricks Kristin

GHP

McGill University

Hendy Geoffrey

Medicine

RI-MUHC, McGill

Ho Ming-Kai

CTB

RI-MUHC

Hodgins Breanna

Experimental Medicine

McGill

Hoque Nowrin

Microbiology

McGill University

Hou Wenyang

Human Genetics

McGill University

Houle Daniel

Medicine

RI-MUHC

Huang Daniel

Microbiology and Immunology

McGill University

Huang Fang

RCP

RI-MUHC

Huddart Sophie

Epidemiology

McGill

Hudson Marie

Medicine

JGH and LDI

Iacovella Andria

Interfax Systems Inc

Ikonomovski Slagjana

Novus Biologicals Canada

Iourtchenko Ekaterina

RI-MUHC

Istomine Roman

Microbiology and Immunology

McGill

Jerome Joseph

Interfax Systems Inc

Johnson Lyne

Pall

Joung Kwang-Bo

Medicine
RI-MUHC

Jusu Sylvester

Medicine
RI

Kachmar Linda

Meakins-Christie lab
RI-MUHC

Kanagaratham Cynthia

Human Genetics
RI-MUHC

Kant Sanket

Experimental Medicine
McGill University

Karatzas Costas

Administration
RI-MUHC

Keser Vafa

Human Genetics
McGill University

Khazaei Sima

Human Genetics
McGill University

Khoja Zehra

Surgery and Neuroscience
RI-MUHC

Kiani Zahra

Experimental Medicine
McGill

Klein Marina

Medicine/Clinical Epidemiology
MUHC

Klimova Natalia

Experimental Medicine
McGill, RI-MUHC

Kokinov Nikola

Microbiology & Immunology
McGill

Kremer Richard

Medicine
MUHC

Krief Joanne

IDIGH
RI-MUHC

Kwong Kelly

MIMM
McGill

Lachapelle Benoit

BD Biosciences

Lacombe Marie-Helene

RI-MUHC

Lai Preston

Diamed Lab Supplies

Lam Steven

Robic

Lan Jack

SARSTEDT

Larivière Mathieu

Thermo Fisher Scientific

Laroche-Pierre Stephanie

Global Health Programs
McGill University

Layoun Antonio

McGill

Le Mauff François

Microbiology and Immunology
McGill

Leblond Eric

Illumina Inc.

LEBOUCHE Bertrand

Department of Family Medicine
Glen Hospital

Leeks Chris

Experimental Medicine
McGill

Lemieux Genevieve

Canadian Life Science

Lemieux Maxime

Medicine
RI-MUHC, McGill

Lemoine Isabelle

Thermo Scientific

Lepage Pierre

Génome Québec

Lesnick John

Drug Discovery
Labcyte Inc.

Li Qing

Experimental Medicine
RI-MUHC

Li Tong

RI-MUHC

Li Xinfang

Urology
RI-MUHC

Lian Jing

ENT
MUHC

Libman Michael

Medicine
Centre for Tropical Diseases

Lin Rongtuan

Medicine
LDI

Lira Alonso

Microbiology and Immunology
McGill University

Liu Jing

Medicine
RI-MUHC

lopez Vanessa

Experimental Medicine
McGill University

Lu Lucy

Promega Corporation

Lu Yan

McGill

Mabanga Tsoarello

Experimental Medicine
RI-MUHC

Maier Mirela

Experimental Medicine
McGill

Martel Caroline

MIMM
RI-MUHC - IDIGH Program

Martel Nathalie

RI-MUHC

Martins Dorival, Junior

Microbiology and Immunology
McGill

MASON HELEN

Microbiology Immunology
McGill

Massicotte Angie

CVIS
RI-MUHC

Matusovskiy Oleg

Medicine
Meakins-Christie Laboratories,
McGill University

Mayaki Dominique

RESP Division
RI MUHC

Mazer Bruce

Allergy Immunology
RI-MUHC/McGill University

McKenzie Marcia

Experimental Medicine
RI-MUHC

Mehraj Vikram

Medicine
RI-MUHC

Mendonca Laura

Microbiology and Immunology
RI-MUHC

Menhem Nadine

Bio-Rad Laboratories

Milad Martin

BioTek Inc.,

Misonne Xavier

Sales
SCIEX

Moarbes Vanessa

Experimental Medicine
MUHC, McGill

Mouland Andrew

Medicine
LDI McGill

Munir Aqsa

Experimental Medicine
McGill University

Napa Diana

Thermo Fisher Scientific

Narayanan Venkatesan

Experimental Medicine
RI-MUHC

Nash Madlen

Microbiology
McGill University

Nath-Chowdhury Milli

Infectious Diseases
Research Institute of the MUHC

Navarro Jose

Medicine - Rheumatology
McGill University

Ndao Momar

Medicine
RI-MUHC and McGill

Negi Sarita

RI-MUHC

Neumann Andrea

Pediatrics/Experimental Medicine
RI-MUHC

Nguyen Christine

VWR

Nguyen Dao

Medicine
McGill

Ni Xiaoyan

RI OF MUHC

Olivier Martin

Medicine
RI-MUHC

Opu Touhidur Rashid

Experimental Medicine
McGill University

Orlova Marianna

RI-MUHC

Ostapska Hanna

Microbiology and Immunology
McGill

Otter Marlies

Medicine
RI-MUHC

Owji Parissa

Neuroscience (IPN)
McGill University/Montreal Children
Hospital

Pacis Alain

Biochemistry
Université de Montréal

Pai Madhu

Faculty of Medicine
McGill and RI-MUHC

Palica Frederick

Thermo Fisher Scientific

Panariti Alice

McGill

Papadopoulos Vassilios

Executive Office
RI-MUHC

Papenburg Jesse

Pediatrics
McGill University

Pare Michel

RI-MUHC

Pennell Leesa

Antibodies
BioLegend

Pernet Erwan

Medicine
McGill University

Pessina Katarina

Experimental Medicine
McGill

Piccirillo Ciro

Microbiology and Immunology
RI-MUHC and McGill University

PILLET STÉPHANE

Infection & Immunity
RI-MUHC

PONTE Rosalie

Experimental Medicine
Research Institute of the McGill
University Health Centre

Posner Barry

Medicine
McGill University

Pruszynska Aleksandra

Human Nutrition
McGill University

Qureshi Salman

Medicine
RI-MUHC

Rached-d'Astous Leïla

McGill University

Radetskyy Roman

Experimental Medicine
McGill, Lady Davis Institute

Radzioch Danuta

Medicine
McGill. Human Genetics

Randolph Haley

Biochemistry
Université de Montréal

Raposo Marco

Clinical
Illumina

Rauch Joyce

Medicine
McGill

Rea Sonia

RI-MUHC

Reed Michael

Infectious Diseases
RI-MUHC

Restori Katherine

Experimental Medicine
McGill

Ricciardi Alessandra

Microbiology & Immunology
McGill University

Ricciardi Riccardo

Flow Cytometry
Sony Biotechnology

Ripa Annie

PeprTech Inc.

Robidoux Frederick

Client Magement Office
Genome Quebec

Rochette Pierre-Alexandre

New England Biolabs

Roland Sharen

Genome Quebec

Rousseau Manon

Thermo Fisher

Rousseau Yvan

Clinical expert in Cell Therapy
Fresenius Kabi Canada Ltd

Routy Jean-Pierre

Medicine
RI-MUHC, McGill

Roy Emmanuel

Diamed Lab Supplies

Ruiz Lancheros Elizabeth

National Reference Center for
Parasitology
RI-MUHC

Rupp Martin

Medicine
McGill

Ruppert Noel

Marketing/Applications
Labcyte Inc.

Russo Cathy

Human Genetics
McGill University Research Institute

Saadé Ziad

Interfax Systems Inc.
(PharmaMedSci Group)

Sabbagh Sébastien

Canadian HIV Cure Enterprise
(CanCURE)

Sabourin France

Merck Canada Inc

Salim Ali

Technical Services
RI-MUHC

Sanchez Veronica

Experimental Medicine
McGill

Sapir-pichhadze Ruth

Medicine
McGill

Sarker Hrishov

Epidemiology, Biostatistics and
Occupational Health
McGill

Scarborough Robert

Microbiology and Immunology
McGill University, Lady Davis
Institute

Scarlata Eleonora

Urology
RI-MUHC

Schurr Erwin

Medicine
RI-MUHC

Sebastiani Giada

Medicine
McGill University

Senhaji Mouhri Zhor

Medicine
McGill

Shan Jichuan

Meakins-Christie Laboratories
RI-MUHC

Shao Qin

Pathology
McGill University Health Centre
Research Institute

Shao Steven

Microbiology and Immunology
McGill University

Shao Yufang

Novoprotein

Sheng Kai

EXMD
MCGILL

Sheppard Don

Medicine
RI-MUHC and McGill

Simard André

Data Management
RI-MUHC

Simons Brigitte

Sales
SCIEX

Skarpetas Andrew

Essen Bioscience

Smith Michael

Illumina

Snarr Brendan

Microbiology & Immunology
McGill University

Solar Ward

Sales
Labcyte Inc.

St-Jacques Bruno

Wisent Inc

Stavrakos Vivian

Department of Medicine
McGill University

Stewart James

Experimental Medicine
McGill

Stolk Annick

Canadian Life Science

Tanaka Ken-Ichiro

Calcium Laboratory
MUHC

Taubner Anne

MiltenyiBiotec

Tian Jun

Experimental Medicine
McGill University

Togun Toyin

Epidemiology, Biostatistics and
Occupational Health
McGill University

Tokhmafshan Fatima

Human Genetics
McGill

Tran Luan

Human Genetics
McGill University

Tsoukas Chris

Medicine
RI-MUHC and McGill

Vasquez Fabio

Parasitology
McGill-MUHC

Vidal Silvia

Human Genetics
McGill Life Sciences Complex

Villeneuve Tania

MJSBioLynx Inc.

Vinh Don

Medicine
RI-MUHC

Ward Brian

Faculty of Medicine
McGill, RI-MUHC and JD McLean

Wells Charles

Infectious Diseases Therapeutic Unit
Sanofi USA

Wilian Correa de Macedo

Biochemistry
McGill

Winter Kaitlin

Microbiology and Immunology
McGill University

Wright Jennifer

Manufacturer/Distributor

Xing Li

RI-MUHC

Xue Di

EXMD
McGill University

Yang Harry

Microbiology and Immunology
McGill University

Yazdani Armin

Neuroscience
McGill

Yousef Mina

Medicine
RI-MUHC, McGill

Zacharias Caitlin

Microbiology and Immunology
McGill University

Zaharatos Gerasimos Jerry

Divisions of Infectious Disease &
Medical Microbiology, Medicine
JGH & LDI

Zealey Chris

Biotechnology
McGill

Zelt Nicholas

MIMM
McGill

Zhang Rui

Experimental Medicine
McGill

Zhang Shizhu

Department of Medicine
RI-MUHC
